Clinical Trial Update: Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

Phase 4 trial assesses tapering rituximab in rheumatoid arthritis, comparing interval prolongation-based taper to disease-activity-guided dose reduction; trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Rheumatoid Arthritis | Phase 4 | Status: RECRUITING